This study focuses on patients with Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) who have already received previous treatments. The study specifically targets patients whose cancer has a particular genetic feature called homozygous MTAP deletion, which means certain genes in the cancer cells are missing. The treatment being tested is BMS-986504 (also known as MRTX1719), which is given as a film-coated tablet that patients take by mouth.

The main purpose of this research is to evaluate how well different doses of BMS-986504 work in treating this specific type of lung cancer. The medication will be given to patients whose cancer has continued to grow or spread despite previous treatments. This is an open-label study, which means both doctors and patients will know which treatment is being given.

During the study, patients will take the medication and have their cancer monitored regularly to see how it responds to the treatment. Doctors will track if the tumors shrink, stay the same size, or grow. They will also monitor how patients feel and any side effects they may experience. The study will look at various aspects of the treatment’s effectiveness, including how long the cancer stays controlled and how long patients survive after starting the treatment.